When to Start: Timing May Shape the Benefits of Blood Transfusion After Brain Injury

For decades, intensive care physicians have treated anemia in patients with severe brain injuries with a kind of clinical caution bordering on superstition. The general rule in critical care has been to withhold red blood cell transfusions until hemoglobin levels fall below 7 grams per deciliter, a restrictive approach validated in broad populations of critically ill adults. But the injured brain is not ordinary tissue. It demands a disproportionate share of the body’s oxygen supply, it cannot store energy, and it is uniquely vulnerable to the secondary damage that follows even brief periods of oxygen deprivation. When hemoglobin drops, the brain’s capacity to extract oxygen from blood diminishes, and in a tissue already reeling from trauma or hemorrhage, that shortfall can translate directly into dying neurons. A new analysis published in Neurocritical Care adds a subtle but potentially important wrinkle to this debate: not only how aggressively clinicians transfuse, but when they begin doing so may influence how patients recover.

The study, led by Luigi Zattera and Nekane Romero-Garcia of Hospital Clínic Barcelona and Hospital Clínico Universitario de Valencia, together with Elisa Gouvea Bogossian of Erasme Hospital in Brussels and colleagues across the international TRAIN Study Group, is a post hoc exploratory analysis of the TRAIN randomized clinical trial. That trial, one of the most ambitious efforts to date in neurocritical care, enrolled 820 adults with acute brain injury, spanning traumatic brain injury, aneurysmal subarachnoid hemorrhage, and intracerebral hemorrhage. Participants were randomly assigned to one of two transfusion thresholds: a liberal strategy, in which red blood cells were transfused when hemoglobin fell below 9 grams per deciliter, or a restrictive strategy, with transfusion triggered only below 7 grams per deciliter. The primary endpoint was unfavorable neurological outcome at 180 days, defined as a Glasgow Outcome Scale–Extended score between 1 and 5, a measure that captures everything from death to severe dependence.

The central question of the new subanalysis was deceptively simple: does the interval between intensive care unit admission and randomization, a proxy for how early the transfusion strategy was initiated, modify the effect of the strategy itself? The researchers divided patients into early and late groups using a cutoff of three days, and also treated time as a continuous variable. They then deployed a formidable statistical arsenal, including multivariable logistic regression, propensity score matching, generalized additive models, and segmented regression, to probe whether the timing of strategy initiation shaped outcomes. A formal interaction test assessed whether the benefit of one strategy over the other depended on when it was started.

The headline finding is reassuring for proponents of liberal transfusion: across both early and late randomization groups, the liberal strategy was consistently associated with a lower probability of unfavorable neurological outcome compared with the restrictive approach. Yet the point estimates hinted at something more intriguing. When randomization occurred early, within the first three days of ICU admission, the association was numerically stronger, with an odds ratio of 0.51 and a 95 percent confidence interval of 0.34 to 0.76. In practical terms, patients whose liberal strategy began in the first days of their ICU stay appeared to face roughly half the odds of a poor neurological outcome compared with those managed restrictively, a magnitude of effect that, if confirmed, would be remarkable in a field where many interventions have failed to move the needle on long-term recovery.

The secondary findings paint a nuanced picture of how timing might redirect the benefits of transfusion toward different complications. In the early-randomization group, the liberal strategy was associated with fewer cerebral ischemic events, with an odds ratio of 0.33, along with shorter durations of mechanical ventilation and shorter ICU stays. This aligns neatly with the pathophysiology: early maintenance of higher hemoglobin levels should preserve oxygen delivery to vulnerable brain tissue and reduce the risk of ischemic insults during the period when the injured brain is most metabolically fragile. In the late-randomization group, by contrast, the liberal strategy was associated with lower rates of sepsis, with an odds ratio of 0.33, and acute respiratory distress syndrome, with an odds ratio of 0.39. The authors suggest that in later phases of critical illness, avoiding prolonged anemia may bolster immune function and tissue oxygenation systemically, reducing susceptibility to infection and lung injury rather than directly protecting the brain.

When the researchers modeled time to randomization as a continuous variable, however, the clean categorical signal dissolved. Generalized additive models showed no clear relationship between the timing of randomization and unfavorable neurological outcome, and the formal interaction test between transfusion strategy and timing was emphatically null, with a p value of 0.88. In other words, the data do not prove that earlier initiation amplifies the benefit of liberal transfusion; they merely suggest a possibility that the study was not powered to confirm. This is the classic tension of post hoc analyses: the categorical split at three days is arbitrary, and any apparent gradient could reflect confounding by illness severity, treatment intensity, or chance.

Perhaps the most provocative result emerged from the exploratory exposure–response analyses. Rather than asking when the strategy began, these models asked how much hemoglobin exposure patients actually accumulated. The findings suggested that greater cumulative exposure to hemoglobin levels above 9 grams per deciliter during the ICU stay was associated with a lower probability of unfavorable neurological outcome. This reframing shifts attention from the transfusion trigger, the moment a clinician decides to transfuse, to the hemoglobin trajectory itself, the integrated oxygen-carrying capacity maintained over days to weeks. It is a conceptually elegant idea: the brain may care less about individual transfusion decisions than about the sustained adequacy of oxygen delivery throughout the vulnerable period of recovery.

The biological rationale for these observations is grounded in well-established physiology. Hemoglobin is the sole carrier of oxygen in blood, and cerebral oxygenation depends on the product of hemoglobin concentration, cardiac output, and cerebral blood flow. Studies using brain tissue oxygen monitoring have shown that anemia after traumatic brain injury is associated with reduced brain tissue oxygen tension and, in some patients, transfusion produces variable but measurable improvements in cerebral oxygenation. Anemia has also been linked to altered cerebral metabolism and worse outcomes in aneurysmal subarachnoid hemorrhage, where delayed cerebral ischemia compounds the initial bleed. At the cellular level, severe anemia triggers eryptosis, a programmed death of red blood cells that further reduces oxygen-carrying capacity and promotes microvascular dysfunction. Against this backdrop, the fear of transfusion, driven by risks of transfusion-associated circulatory overload, acute lung injury, and immunomodulation, has long created a genuine clinical dilemma with plausible harms on both sides.

Context matters for interpreting the new results. The original TRAIN trial, published in JAMA in 2024, reported that a liberal strategy was associated with fewer ischemic events and a trend toward better neurological outcomes, while subsequent secondary analyses in intracerebral hemorrhage and subarachnoid hemorrhage subgroups, along with updated meta-analyses, have generally supported the safety and potential benefit of higher hemoglobin targets in neurocritical patients. Meanwhile, trials in aneurysmal subarachnoid hemorrhage published in the New England Journal of Medicine in 2025 have added to a shifting consensus that the restrictive thresholds borrowed from general critical care may be too low for the injured brain. The new subanalysis fits into this evolving landscape by raising a question that the parent trial was never designed to answer: whether the clock starts ticking on the brain’s vulnerability from the moment of injury, making early hemoglobin optimization disproportionately valuable.

The authors are appropriately measured in their conclusions. They emphasize that timing to randomization may influence the impact of transfusion strategies and the occurrence of some adverse events, but that prospective studies specifically designed to address this question are needed before any change in practice. Post hoc analyses generate hypotheses; they do not settle them. Still, the implications for trial design are concrete: future studies might randomize patients at the bedside within hours of ICU admission, stratify by time to intervention, and measure cumulative hemoglobin exposure as a primary pharmacodynamic variable. For the roughly millions of people worldwide who sustain severe traumatic brain injuries, aneurysmal subarachnoid hemorrhages, and intracerebral hemorrhages each year, the stakes of this line of research are enormous. A simple, inexpensive intervention, adjusting when and how aggressively hemoglobin is maintained, could meaningfully alter the trajectory of recovery in a condition where most therapeutic advances have come from meticulous attention to physiology rather than dramatic new drugs. The TRAIN subanalysis does not rewrite the guidelines, but it sharpens the question that neurointensivists will be asking in the years ahead: not just how much hemoglobin is enough, but how soon it must be enough.

Subject of Research: Timing of red blood cell transfusion strategy initiation and neurological outcomes in acute brain injury

Article Title: Timing of Transfusion Strategy Initiation in Acute Brain Injury: A Subanalysis of the TRAIN Study

Article References: Zattera, L., Romero-Garcia, N., Gabarrus, A., Quintana Diaz, M., Barbeta, E., González-Magdalena, A., Moller, K., Kurtz, P., Torres, A., Fernandez, L., Ferrando, C., Caricato, A., Badenes, R., Lormans, P., Quintard, H., Amaro, S., Cinotti, R., Videtta, W., Llull, L., … Massimo Antonelli (2026). Timing of Transfusion Strategy Initiation in Acute Brain Injury: A Subanalysis of the TRAIN Study. Neurocritical Care. https://doi.org/10.1007/s12028-026-02651-8

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02651-8

Keywords: acute brain injury, blood transfusion, hemoglobin threshold, TRAIN trial, neurocritical care, traumatic brain injury, subarachnoid hemorrhage, intracerebral hemorrhage, anemia, neurological outcome, randomized clinical trial, ICU